Ursula von der Leyen: UK is Covid vaccine
'speedboat' compared with EU 'tanker'
European commission’s president admits it
underestimated difficulties in vaccine rollout
Daniel
Boffey in Brussels
Fri 5 Feb
2021 13.56 GMT
Ursula von
der Leyen has said a country on its own such as the UK can act more like a
“speedboat” than the EU “tanker” but that the 27 governments are right to work
together on their vaccination programme.
The
European commission president admitted to mistakes along the way in the rollout
of vaccines, including failing to invest sufficiently in upscaling production
capacity.
She also
conceded that the commission “underestimated the difficulties” it would face
and should have warned the public in advance of the likely “ups and downs”.
But, in an
interview with nine European newspapers, she defended Brussels against recent
criticism that it had gone too slowly in agreeing contracts in light of a deal
being agreed between the UK and AstraZeneca three months before the bloc.
Von der
Leyen, a former German defence minister, said that while collective
decision-making could be cumbersome, it ensured poorer EU countries were not
left behind, according to the French newspaper La Croix.
“I am aware
that alone a country can be a speedboat, while the EU is more like a tanker,”
Von der Leyen said. “Before concluding a contract with a pharmaceutical
company, the 27 member states had five full days to say whether they agreed or
not.
“This
naturally delays the process. Indeed, we must constantly put pressure on
ourselves so that each step of the decision-making process is as fast and
efficient as possible.
“But I am
absolutely convinced that the European approach is the right one. On these
vaccines, we worked faster than usual. I can’t even imagine what it would have
meant for Europe, in terms of unity, if one or more member states had access to
vaccines and not the others.”
The EU has
administered vaccines to 3.22% of its adult population, compared with 15.5% who
have had a first jab in the UK. Israel has administered a jab to 60% of its
population.
Von der
Leyen said the chief cause of the difference in timescales between the EU and
the UK was the slower authorisation process undertaken by the European
Medicines Agency than that open to national regulators.
She said:
“The UK has chosen the route of emergency marketing authorisations. We have
chosen another, and we believe it is the right one.
“Israel is
also often cited as a model of success. The country is highly digitalised – and
that’s good – but personal health data is given to companies there. This is not
something we would want to do in the EU.”
Figures
compiled by the data analytics company Airfinity suggest that the US has
invested nine times as much as the EU in upscaling manufacturing vaccines
although the figures have been disputed by the commission.
But Von der
Leyen admitted that the bloc should have put more money into upscaling
capacity.
“What I
realise, looking in the rearview mirror, is that we should have thought more,
in parallel, about mass production and the challenges it poses,” she said. “The
industry has never suddenly embarked on such a gamble …
“To
increase volumes, to set up new supply chains sufficiently upstream, we could
have done it earlier. Now we are working with industry to prepare for the
possibility of variants of the coronavirus that can resist vaccines.
“We must
immediately support science, so that vaccines are adapted as quickly as
possible. Because the best lesson learned in recent months is that you never
know what will happen in a year. We must be prepared for all eventualities.”
Last week,
the commission had to U-turn on an a move to trigger article 16 of the Northern
Ireland protocol in the Brexit withdrawal agreement as part of its attempt to
control vaccine exports out of the bloc.
The EU’s
executive branch wanted to temporarily override the terms of the treaty to
establish a vaccine border on the island of Ireland to ensure that Northern
Ireland could not be used as a backdoor for vaccine exports to the UK.
“We
shouldn’t even have thought about article 16,” she said. “I regret it. The
commission took around 1,500 decisions in a short period of time and almost 900
emergency decisions under very high pressure.”
Meanwhile,
during an awkward trip to Moscow, the EU’s high representative for foreign
affairs Josep Borrell welcomed the development of Russia’s Sputnik vaccine,
adding that it would be welcome given the bloc as “facing a shortage of
vaccines”.
“It’s good
news for the whole of mankind because it means we will have more tools to fight
the pandemic,” he said.
Sergei
Lavrov, Russia’s foreign minister, said that several European countries were
“interested in producing the vaccine on their territory”.
The Czech
prime minister, Andrej Babiš, said it may consider giving emergency approval to
vaccines not approved by the EU regulator while on a visit to Hungary, which is
using both the Russian and Chinese vaccines.
“I have
spoken about the Russian vaccine, and about the Chinese vaccine, with
Chancellor Merkel, and the chancellor as well as the Bavarian prime minister
are unambiguously calling for this vaccine to be approved by the European
Medicines Agency,” Babiš said.
“Now of
course the issue is whether the producer asks for the approval or not, and we
of course want to consider, if we get hold of the vaccine, to go the similar
way as Hungary did because time is of essence.”


Sem comentários:
Enviar um comentário